若不治疗耐多药结核病的危险。
The risk of leaving multidrug-resistant tuberculosis untreated.
应对耐多药结核病方面取得的进展
但这些病例中有多少是耐多药结核病？
预防和控制耐多药结核病和广泛耐药结核病。
Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
因此，出现各种耐多药结核病管理不善的情况。
As a result all kinds of poor management of MDR-TB are happening.
问：你什么时候开始介入耐多药结核病问题的？
这就是耐多药结核病的出现和传播所带来的前景。
This is the perspective created by the emergence and spread of drug-resistant tuberculosis.
问：你对与耐多药结核病作斗争的前途有什么看法？
问：哈萨克斯坦与耐多药结核病作斗争的核心内容是什么？
Q: What's the most important part of Kazakhstan's fight against drug-resistant TB?
耐多药结核病是一种对一线标准药物没有反应的结核病形式。
MDR-TB is a form of TB that fails to respond to standard first-line drugs.
结核病规划在减少耐多药结核病发病率方面面临着巨大挑战。
Tuberculosis programmes face tremendous challenges in reducing MDR-TB rates.
菲律宾像世界任何国家一样，长期以来设法控制耐多药结核病。
The Philippines has tried to control multidrug-resistant TB (MDR -TB ) for nearly as long as any country in the world.
到2008年底，耐多药结核病项目总共治疗了1316例病人。
By the end of 2008, the MDR-TB project had treated 1316 patients in all.
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
6个月疗程结束后的仅数月内，他再次病倒，这次是耐多药结核病。
Only a few months after finishing his six-month treatment, Gagarin became sick again – this time with MDR-TB.
结核病控制在稳步取得进步，但耐多药结核病却达到了历史较高水平。
Progress in tuberculosis control remains steady but multi-drug resistant TB has reached historic levels.
耐多药结核病的蔓延引起了人们的特别关注，尤其是在东欧、中亚部分和中国。
The spread of multi-drug resistant TB is a cause of particular concern, especially in Eastern Europe, parts of Central Asia, and China.
世卫组织今年早些时候发布的一个报告表明，耐多药结核病发病率已达到记录新高。
Earlier this year, WHO issued a report showing that multi-drug resistant TB has reached the highest levels ever recorded.
为了支持北京会议的目标，帮助各国扩展耐多药结核病控制的计划工具正在开发中。
In support of the Beijing meeting's aims, planning tools are being developed to help countries scale up their MDR-TB control efforts.
然而，还需要进行更多研究才能确定耐多药结核病和艾滋病在全球的流行是否有重叠。
However, more research is needed to determine whether there is an overlap between the MDR-TB and HIV epidemics worldwide.
世卫组织估计，2011年至2015年之间将有200多万耐多药结核病新发病例。
WHO estimates there will be more than 2 million new cases of MDR-TB between 2011 and 2015.
感染艾滋病毒者罹患耐多药结核病的风险较大，其死亡率大幅上升，存活时间大大减少。
People living with HIV have a higher risk of MDR-TB, with a greatly increased mortality and a greatly reduced survival time.
耐多药结核病是所有国家面临的一个挑战，这是由于该病治疗起来存有难度并且费用昂贵。
MDR-TB is a threat to all countries as it is difficult and expensive to treat.
每年出现约44万耐多药结核病(MDR - TB)新发病例，至少造成15万例死亡。
About 440 000 new cases of multidrug-resistant tuberculosis (MDR-TB) emerge annually, causing at least 150 000 deaths.
用于疗耐多药结核病漫长治疗的药品费用比治疗常见结核病菌株的药品可能贵100倍以上。
The drugs for the lengthy treatment of MDR-TB can cost more than 100 times that of the drugs to treat common tuberculosis strains.
耐多药结核病是由对多数有效抗结核病药物（异烟肼和利福平）都具有耐药性的细菌引起的。
MDR-TB is caused by bacteria that are resistant to the most effective anti-TB drugs (isoniazid and rifampicin).
患者往往尚未得知检测结果即已死亡，尤其是那些既患有耐多药结核病又感染了艾滋病毒的患者。
Often the patients die before results are known, especially if they are HIV-infected in addition to having MDR-TB.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
应用推荐